MX379176B - Una triazolopiridazina como un modulador de cinasa - Google Patents

Una triazolopiridazina como un modulador de cinasa

Info

Publication number
MX379176B
MX379176B MX2017007114A MX2017007114A MX379176B MX 379176 B MX379176 B MX 379176B MX 2017007114 A MX2017007114 A MX 2017007114A MX 2017007114 A MX2017007114 A MX 2017007114A MX 379176 B MX379176 B MX 379176B
Authority
MX
Mexico
Prior art keywords
compounds
met
subject
cell
triazolopyridazine
Prior art date
Application number
MX2017007114A
Other languages
English (en)
Other versions
MX2017007114A (es
Inventor
Ioannis Nicolaos Houpis
Lieven Meerpoel
Patrick Blasius Furer
Philip James Pye
Ronaldus Arnodus Hendrika Joseph Gilissen
Timothy Pietro Suren Perera
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017007114A publication Critical patent/MX2017007114A/es
Publication of MX379176B publication Critical patent/MX379176B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se dirige a un compuesto de triazolopiridazina de la fórmula (I): ver fórmula (I) 10 N-óxidos, sales farmacéuticamente aceptables y solvatos de los mismos, en donde D representa deuterio, al uso de tales compuestos como moduladores de la proteína tirosina cinasa, particularmente inhibidores de c-Met, y al uso de tales compuestos para reducir o inhibir la actividad cinasa de c-Met en una célula o un sujeto, y para modular la expresión de c-Met en una célula o un sujeto, y al uso de tales compuestos para prevenir o tratar en un sujeto un trastorno proliferativo celular y/o trastornos relacionados con c-Met. La presente invención se dirige además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para tratar condiciones tales como cánceres y otros trastornos celulares proliferativos.
MX2017007114A 2014-12-04 2015-12-03 Una triazolopiridazina como un modulador de cinasa MX379176B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196387 2014-12-04
EP14196585 2014-12-05
PCT/EP2015/078525 WO2016087586A1 (en) 2014-12-04 2015-12-03 A deuterated triazolopyridazine as a kinase modulator

Publications (2)

Publication Number Publication Date
MX2017007114A MX2017007114A (es) 2018-05-02
MX379176B true MX379176B (es) 2025-03-11

Family

ID=54771127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007114A MX379176B (es) 2014-12-04 2015-12-03 Una triazolopiridazina como un modulador de cinasa

Country Status (22)

Country Link
US (2) US10138246B2 (es)
EP (1) EP3227296B1 (es)
JP (1) JP6795502B2 (es)
KR (1) KR102643179B1 (es)
CN (1) CN107108632B (es)
AU (1) AU2015357085B2 (es)
BR (1) BR112017010849B1 (es)
CA (1) CA2968294C (es)
DK (1) DK3227296T3 (es)
EA (1) EA033193B1 (es)
ES (1) ES2795666T3 (es)
HU (1) HUE050285T2 (es)
IL (1) IL252356B (es)
MX (1) MX379176B (es)
MY (1) MY183207A (es)
PL (1) PL3227296T3 (es)
PT (1) PT3227296T (es)
SG (1) SG11201704078XA (es)
SI (1) SI3227296T1 (es)
TW (1) TWI695837B (es)
WO (1) WO2016087586A1 (es)
ZA (1) ZA201703386B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI695837B (zh) * 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
CN106279176B (zh) * 2015-06-11 2020-09-08 中国科学院上海药物研究所 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
WO2022140528A1 (en) * 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN116848110A (zh) * 2020-12-23 2023-10-03 建新公司 氘代集落刺激因子-1受体（csf-1r）抑制剂
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
CA2216943C (en) 1995-04-19 2003-06-17 Boston Scientific Limited Drug release coated stent
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
PT1966214T (pt) * 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
EP2170894A1 (en) * 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
TWI695837B (zh) * 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒

Also Published As

Publication number Publication date
ZA201703386B (en) 2021-07-28
PT3227296T (pt) 2020-06-17
IL252356A0 (en) 2017-07-31
SI3227296T1 (sl) 2020-09-30
CN107108632A (zh) 2017-08-29
BR112017010849B1 (pt) 2023-12-12
MY183207A (en) 2021-02-18
PL3227296T3 (pl) 2020-09-21
US10138246B2 (en) 2018-11-27
CA2968294A1 (en) 2016-06-09
IL252356B (en) 2020-03-31
MX2017007114A (es) 2018-05-02
BR112017010849A2 (pt) 2018-01-09
CN107108632B (zh) 2022-04-19
WO2016087586A1 (en) 2016-06-09
TW201636350A (zh) 2016-10-16
EA201791179A1 (ru) 2017-09-29
DK3227296T3 (da) 2020-06-08
CA2968294C (en) 2023-09-19
HUE050285T2 (hu) 2020-11-30
JP6795502B2 (ja) 2020-12-02
AU2015357085A1 (en) 2017-07-27
KR20170123606A (ko) 2017-11-08
US20190031670A1 (en) 2019-01-31
SG11201704078XA (en) 2017-06-29
ES2795666T3 (es) 2020-11-24
US20170267684A1 (en) 2017-09-21
TWI695837B (zh) 2020-06-11
EP3227296A1 (en) 2017-10-11
NZ733447A (en) 2023-09-29
JP2017537112A (ja) 2017-12-14
EP3227296B1 (en) 2020-03-04
US10464939B2 (en) 2019-11-05
AU2015357085B2 (en) 2020-01-30
EA033193B1 (ru) 2019-09-30
KR102643179B1 (ko) 2024-03-04

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
MX2023006257A (es) Inhibidores de smyd.
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
EA201290103A1 (ru) Гетероциклические соединения и их использование
EA201690752A1 (ru) Ингибиторы g12c kras
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
EA201591823A1 (ru) Ингибиторы ido
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
CO7160047A2 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr)
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA201690306A1 (ru) Ингибиторы ido
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX379176B (es) Una triazolopiridazina como un modulador de cinasa
MX2015005841A (es) Compuestos y composiciones terapeuticos y su uso como moduladores pkm2.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MX2017002986A (es) Compuestos de piperidina sustituidos.
MX390051B (es) Antagonistas de ep4.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2